Skip to main content
LQDA
NASDAQ Life Sciences

Liquidia Posts $74.7M Q2 Profit as YUTREPIA Sales Surge to $170.4M

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$90.39
Mkt Cap
$7.83B
52W Low
$19.9
52W High
$93.61
52W Position info
354% above low
Off High info
3.4% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $19.9.

Summary

Liquidia delivered a strong Q2 with net income of $74.7 million, its fourth straight profitable quarter, driven by YUTREPIA net product sales of $170.4 million — up from $6.5 million a year ago. The inhaled prostacyclin market has grown nearly 40% since launch, and YUTREPIA has captured an increasing share, with over 5,000 patients started on treatment and more than 1,100 prescribers. Cash rose to $284.2 million, providing ample runway. The company also began enrolling patients in the Re-Spire pivotal study for L606, its next-generation inhaled therapy. This follows a period of heavy insider selling, but the commercial momentum and pipeline progress may shift focus back to fundamentals. The earnings call at 8:30 a.m. ET today will provide further color on guidance and litigation updates.

At the time of this announcement, LQDA was trading at $90.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $19.90 to $93.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.45
Real-time Price: $54.75 info
Change: +$7.30 (+15%) info
Market Cap: $4.904B info
LQDA
Nov 10, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.40
Real-time Price: $54.75 info
Change: +$7.35 (+16%) info
Market Cap: $4.904B info
LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $54.75 info
Change: +$4.75 (+10%) info
Market Cap: $4.904B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $54.75 info
Change: +$15.25 (+39%) info
Market Cap: $4.904B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $54.75 info
Change: +$22.99 (+72%) info
Market Cap: $4.904B info